TXK

Summary

Gene Symbol: TXK
Description: TXK tyrosine kinase
Alias: BTKL, PSCTK5, PTK4, RLK, TKL, tyrosine-protein kinase TXK, PTK4 protein tyrosine kinase 4, protein-tyrosine kinase 4, resting lymphocyte kinase
Species: human
Products:     TXK

Top Publications

  1. Ohta Y, Haire R, Amemiya C, Litman R, Träger T, Riess O, et al. Human Txk: genomic organization, structure and contiguous physical linkage with the Tec gene. Oncogene. 1996;12:937-42 pubmed
    b>Txk is a Tec-family tyrosine kinase expressed in mouse and human T lymphocytes...
  2. Schneider H, Schwartzberg P, Rudd C. Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4. Biochem Biophys Res Commun. 1998;252:14-9 pubmed
    ..In this study, we demonstrate that Rlk (resting lymphocyte kinase) is capable of phosphorylating CTLA-4 at the YVKM motif...
  3. Schneider H, Guerette B, Guntermann C, Rudd C. Resting lymphocyte kinase (Rlk/Txk) targets lymphoid adaptor SLP-76 in the cooperative activation of interleukin-2 transcription in T-cells. J Biol Chem. 2000;275:3835-40 pubmed
    b>Rlk/Txk is a T-cell-specific member of the Btk/Tec family of tyrosine kinases, whereas SLP-76 is a lymphoid adaptor that is essential for pre-TcR and mature TcR signaling...
  4. Haire R, Ohta Y, Lewis J, Fu S, Kroisel P, Litman G. TXK, a novel human tyrosine kinase expressed in T cells shares sequence identity with Tec family kinases and maps to 4p12. Hum Mol Genet. 1994;3:897-901 pubmed
    A gene for a novel, putative cytoplasmic tyrosine kinase, TXK has been isolated from a human peripheral blood cDNA library...
  5. Kayabasi C, Okcanoglu T, Yelken B, Aşık A, Susluer S, Avci C, et al. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia. Gene. 2017;637:173-180 pubmed publisher
    ....
  6. Narra R, Flynn K, Atallah E. Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. Curr Hematol Malig Rep. 2017;12:415-423 pubmed publisher
    ..Recently several studies have shown the feasibility and safety of discontinuation in a select group of patients. Herein, we will review the currently available data on stopping TKIs in CML. ..
  7. Li J, Chen S, Ge J, Lu F, Ren S, Zhao Z, et al. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect. Vaccine. 2017;35:6459-6467 pubmed publisher
    ..In summary, this study found that Flt3L-RM16 fusion protein is a promising therapeutic vaccine for immunotherapy of HPV16-associated cervical cancer...
  8. Uy G, Mandrekar S, Laumann K, Marcucci G, Zhao W, Levis M, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017;1:331-340 pubmed publisher
    ..This trial was registered at www.clinicaltrials.gov as #NCT01253070...
  9. Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017;51:1357-1369 pubmed publisher
    ....
  10. Bryan K, Jarboui M, Raso C, Bernal Llinares M, McCann B, Rauch J, et al. HiQuant: Rapid Postquantification Analysis of Large-Scale MS-Generated Proteomics Data. J Proteome Res. 2016;15:2072-9 pubmed publisher
    ..Download HiQuant, sample data sets, and supporting documentation at http://hiquant.primesdb.eu . ..

Detail Information

Publications62

  1. Ohta Y, Haire R, Amemiya C, Litman R, Träger T, Riess O, et al. Human Txk: genomic organization, structure and contiguous physical linkage with the Tec gene. Oncogene. 1996;12:937-42 pubmed
    b>Txk is a Tec-family tyrosine kinase expressed in mouse and human T lymphocytes...
  2. Schneider H, Schwartzberg P, Rudd C. Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4. Biochem Biophys Res Commun. 1998;252:14-9 pubmed
    ..In this study, we demonstrate that Rlk (resting lymphocyte kinase) is capable of phosphorylating CTLA-4 at the YVKM motif...
  3. Schneider H, Guerette B, Guntermann C, Rudd C. Resting lymphocyte kinase (Rlk/Txk) targets lymphoid adaptor SLP-76 in the cooperative activation of interleukin-2 transcription in T-cells. J Biol Chem. 2000;275:3835-40 pubmed
    b>Rlk/Txk is a T-cell-specific member of the Btk/Tec family of tyrosine kinases, whereas SLP-76 is a lymphoid adaptor that is essential for pre-TcR and mature TcR signaling...
  4. Haire R, Ohta Y, Lewis J, Fu S, Kroisel P, Litman G. TXK, a novel human tyrosine kinase expressed in T cells shares sequence identity with Tec family kinases and maps to 4p12. Hum Mol Genet. 1994;3:897-901 pubmed
    A gene for a novel, putative cytoplasmic tyrosine kinase, TXK has been isolated from a human peripheral blood cDNA library...
  5. Kayabasi C, Okcanoglu T, Yelken B, Aşık A, Susluer S, Avci C, et al. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia. Gene. 2017;637:173-180 pubmed publisher
    ....
  6. Narra R, Flynn K, Atallah E. Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. Curr Hematol Malig Rep. 2017;12:415-423 pubmed publisher
    ..Recently several studies have shown the feasibility and safety of discontinuation in a select group of patients. Herein, we will review the currently available data on stopping TKIs in CML. ..
  7. Li J, Chen S, Ge J, Lu F, Ren S, Zhao Z, et al. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8+ T cell responses and antitumor effect. Vaccine. 2017;35:6459-6467 pubmed publisher
    ..In summary, this study found that Flt3L-RM16 fusion protein is a promising therapeutic vaccine for immunotherapy of HPV16-associated cervical cancer...
  8. Uy G, Mandrekar S, Laumann K, Marcucci G, Zhao W, Levis M, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017;1:331-340 pubmed publisher
    ..This trial was registered at www.clinicaltrials.gov as #NCT01253070...
  9. Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017;51:1357-1369 pubmed publisher
    ....
  10. Bryan K, Jarboui M, Raso C, Bernal Llinares M, McCann B, Rauch J, et al. HiQuant: Rapid Postquantification Analysis of Large-Scale MS-Generated Proteomics Data. J Proteome Res. 2016;15:2072-9 pubmed publisher
    ..Download HiQuant, sample data sets, and supporting documentation at http://hiquant.primesdb.eu . ..
  11. Ku B, Bae Y, Koh J, Sun J, Lee S, Ahn J, et al. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells. Invest New Drugs. 2016;34:407-15 pubmed publisher
    ..Taken together, our results provide a potential mechanism for the sensitivity of EGFR(L858R/T790M) cells to AZD9291 and suggest that AZD9291 may be effective in cases of T790 M-positive EGFR resistance. ..
  12. Buikhuisen W, Scharpfenecker M, Griffioen A, Korse C, Van Tinteren H, Baas P. A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes. J Thorac Oncol. 2016;11:758-68 pubmed publisher
    ..Interference with angiogenesis may therefore improve outcome. This study reports on clinical and translational parameters in patients treated with the small molecule tyrosine kinase inhibitor axitinib and chemotherapy...
  13. Xu J, Liu X, Yang S, Zhang X, Shi Y. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer. Asia Pac J Clin Oncol. 2017;: pubmed publisher
    ..We further assessed the efficacy and safety of apatinib at a more frequently used dose of 500 mg qd. The preliminary clinical outcome of apatinib in patients with brain metastases was also reported...
  14. Batth I, Yun H, Hussain S, Meng P, Osmulski P, Huang T, et al. Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer. Oncotarget. 2016;7:14048-63 pubmed publisher
    ....
  15. Sarntivijai S, Zhang S, Jagannathan D, Zaman S, Burkhart K, Omenn G, et al. Linking MedDRA(®)-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors. Drug Saf. 2016;39:697-707 pubmed publisher
    ..The ontology of adverse events (OAE) represents AEs as pathological processes occurring after drug exposures...
  16. Ohtani Kaneko R, Sato K, Tsutiya A, Nakagawa Y, Hashizume K, Tazawa H. Characterisation of human induced pluripotent stem cell-derived endothelial cells under shear stress using an easy-to-use microfluidic cell culture system. Biomed Microdevices. 2017;19:91 pubmed publisher
    ....
  17. Jang J, Wang X, VEDELL P, Wen J, Zhang J, Ellison D, et al. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma. J Thorac Oncol. 2016;11:1891-1900 pubmed publisher
    ..We performed a genomic study in lung adenocarcinoma cases with discordant anaplastic lymphoma receptor tyrosine kinase gene (ALK) status by fluorescent in situ hybridization (FISH) and immunohistochemical (IHC) analysis...
  18. Zhang B, Groffen J, Heisterkamp N. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. Blood. 2005;106:1355-61 pubmed
    ..A determination of the expression levels of this gene may have prognostic value when treatment with such classes of drugs is contemplated...
  19. Na Y, Ryu M, Yoo C, Lee J, Park J, Lee C, et al. Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors. Oncotarget. 2017;8:76712-76721 pubmed publisher
    ..Imatinib inhibited the KIT pathway in imatinib-sensitive GIST-T1 but not GIST-RX1, RX2, and RX4. These GIST PDX models will be useful for studying TKI resistance mechanisms and evaluating novel targeted agents in GIST...
  20. Erpenbeck L, Chowdhury C, Zsengellér Z, Gallant M, Burke S, Cifuni S, et al. PAD4 Deficiency Decreases Inflammation and Susceptibility to Pregnancy Loss in a Mouse Model. Biol Reprod. 2016;95:132 pubmed publisher
    ..Inhibition of NETosis may serve as a novel target in disorders of impaired placentation. ..
  21. Yao Z, Darowski K, St Denis N, Wong V, Offensperger F, Villedieu A, et al. A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome. Mol Cell. 2017;65:347-360 pubmed publisher
    ..This comprehensive RTK-phosphatase interactome study provides a broad and deep view of RTK signaling. ..
  22. Ma F, Yu Q, Zeng Z, He R, Mo C, Zhong J, et al. Progression-free survival of up to 8 months of an advanced intrahepatic cholangiocarcinoma patient treated with apatinib: a case report. Onco Targets Ther. 2017;10:5237-5242 pubmed publisher
    ..The only toxicity observed was mild hand-foot syndrome. Therefore, apatinib may be an additional option for the treatment of advanced ICC, but further prospective studies are needed to optimize the treatment...
  23. Patel J. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma. Clin Lung Cancer. 2004;6 Suppl 1:S43-7 pubmed
    ..Furthermore, recent insights into mechanisms of drug sensitivity should impact future clinical trial design...
  24. Théou N, Gil S, Devocelle A, Julie C, Lavergne Slove A, Beauchet A, et al. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res. 2005;11:7593-8 pubmed
    ..These results confirm that gastric and nongastric GISTs have different biological characteristics and suggest that MDR proteins do not impair the initial response of the tumor to imatinib...
  25. DuSablon A, Parks J, Whitehurst K, Estes H, Chase R, Vlahos E, et al. EphrinA1-Fc attenuates myocardial ischemia/reperfusion injury in mice. PLoS ONE. 2017;12:e0189307 pubmed publisher
    ....
  26. Fang Y, Hu Y, Ling L, Chen Y, Shi Y, Zhang L, et al. [Differential Regulation of Bruton's Tyrosine Kinase by the Ubiquitin Pathway]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017;25:1559-1565 pubmed publisher
    ..To investigate the regulation of Bruton's tyrosine kinase (Btk) and to explore its possible mechanism...
  27. Yu H, Sima C, Feldman D, Liu L, Vaitheesvaran B, Cross J, et al. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol. 2017;28:278-284 pubmed publisher
    ..Pulse dose erlotinib has superior central nervous system (CNS) penetration and may result in superior CNS disease control...
  28. Nan X, Xie C, Yu X, Liu J. EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017;8:75712-75726 pubmed publisher
    ....
  29. Campanella N, Scapulatempo Neto C, Abrahão Machado L, Torres de Oliveira A, Berardinelli G, Guimarães D, et al. Lack of microsatellite instability in gastrointestinal stromal tumors. Oncol Lett. 2017;14:5221-5228 pubmed publisher
    ..The results of the present study indicated that MSI is not involved in GIST tumorigenesis and, therefore, cannot serve as a biomarker to immunotherapy response in GIST...
  30. Wang J, Deng R, Cui N, Zhang H, Liu T, Dou J, et al. Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation. Neoplasia. 2017;19:961-971 pubmed publisher
    ..Our results suggest that SUMOylation of Src at lysine 318 negatively modulate its oncogenic function by, at least partially, inhibiting Src-FAK complex activity. ..
  31. Jin J, Ko I, Kim S, Hwang L, Lee M, Kim D, et al. Age-dependent differences of treadmill exercise on spatial learning ability between young- and adult-age rats. J Exerc Rehabil. 2017;13:381-386 pubmed publisher
    ..The results of this study showed that adults have excellent spatial learning abilities than children, but the improvement of exercise-induced spatial learning ability through neurogenesis is better in children...
  32. Zheng Z, Wang H, Jiang H, Chen E, Zhang J, Xie X. Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review. Medicine (Baltimore). 2017;96:e8507 pubmed publisher
    ..Apatinib, a new small molecule tyrosine kinase inhibitor that specifically targets VEGFR-2, has therapeutic benefits in some advanced tumors. However, its efficacy in P-EHE cases has not been reported...
  33. Gondoin A, Hampe C, Eudes R, Fayolle C, Pierre Eugène C, Miteva M, et al. Identification of insulin-sensitizing molecules acting by disrupting the interaction between the Insulin Receptor and Grb14. Sci Rep. 2017;7:16901 pubmed publisher
    ..The use of C8 as a lead compound should allow for the development of new molecules of potential therapeutic interest for the treatment of diabetes. ..
  34. Niinivirta M, Enblad G, Edqvist P, Ponten F, Dragomir A, Ullenhag G. Tumoral ANXA1 Is a Predictive Marker for Sunitinib Treatment of Renal Cancer Patients. J Cancer. 2017;8:3975-3983 pubmed publisher
    ..A possible explanation for this finding is that sunitinibs anti-angiogenic effect cannot overcome the pro-angiogenic drive from many ANXA1 proteins...
  35. Eden G, Archinti M, Arnaudova R, Andreotti G, Motta A, Furlan F, et al. D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR. Cell Mol Life Sci. 2017;: pubmed publisher
    ..Moreover, D2A peptide and EGF phosphorylate ERK demonstrating the involvement of the MAP kinase signalling pathway. Altogether, this study reveals the importance of sequence D2A of uPAR, and the interdependence of uPAR and EGFR...
  36. Belinsky M, Cai K, Zhou Y, Luo B, Pei J, Rink L, et al. Succinate dehydrogenase deficiency in a PDGFRA mutated GIST. BMC Cancer. 2017;17:512 pubmed publisher
    ..This is the first reported case of a PDGFRA mutant GIST exhibiting SDH-deficiency. A brief discussion of the relevant GIST literature is included. ..
  37. Natale R. Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor. Clin Lung Cancer. 2003;5 Suppl 1:S11-7 pubmed
    ..The use of gefitinib in standard treatment programs or combined with other molecular targeted agents may substantially improve the outlook for patients with NSCLC or other types of solid tumors..
  38. Whitman S, Kohlschmidt J, Maharry K, Volinia S, Mrozek K, Nicolet D, et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014;28:1252-1258 pubmed publisher
    ....
  39. Karakus S, Sancakdar E, Akkar O, Yildiz C, Demirpence O, Cetin A. Elevated Serum CD95/FAS and HIF-1α Levels, but Not Tie-2 Levels, May Be Biomarkers in Patients With Severe Endometriosis: A Preliminary Report. J Minim Invasive Gynecol. 2016;23:573-7 pubmed publisher
    ....
  40. Rastogi I, Rajanna S, Webb A, Chhabra G, Foster B, Webb B, et al. Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer. Biochem Biophys Res Commun. 2016;477:937-944 pubmed publisher
    ..Finally, we show that down-regulating Zeb-1 by inducing miR-200a or β-Catenin siRNA can increase drug sensitivity of TKI-resistant cells...
  41. Kim J, Lee M, Jeong B, Oh S, Kook M, Koh J. Chemical inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation and bone regeneration. Eur J Pharmacol. 2017;806:10-17 pubmed publisher
    ..Collectively, our results suggest that chemical inhibitors of c-Met receptor tyrosine kinase might be used as novel therapeutics to induce bone regeneration. ..
  42. Yamaguchi N, Shibazaki M, Yamada C, Anzai E, Morii M, Nakayama Y, et al. Tyrosine Phosphorylation of the Pioneer Transcription Factor FoxA1 Promotes Activation of Estrogen Signaling. J Cell Biochem. 2017;118:1453-1461 pubmed publisher
    ..These results suggest that c-Abl-mediated phosphorylation of FoxA1 promotes the activation of estrogen signaling by inducing its binding to histones. J. Cell. Biochem. 118: 1453-1461, 2017. © 2016 Wiley Periodicals, Inc. ..
  43. Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, et al. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. Int J Cancer. 2018;142:202-213 pubmed publisher
    ..Taken together, simultaneous suppression of BTK and mTOR may be indicated as a potential therapeutic modality for the treatment of MCL...
  44. Cooper S, Sandhu H, Hussain A, Mee C, Maddock H. Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity. Toxicology. 2018;394:72-83 pubmed publisher
    ..Investigations into the ASK1/MKK7/JNK transduction pathway could lead to development of cardioprotective adjunct therapy, which could prevent Sunitinib-induced cardiac injury. ..
  45. Azzariti A, Porcelli L, Simone G, Quatrale A, Colabufo N, Berardi F, et al. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010;65:335-46 pubmed publisher
    ....
  46. Kuang B, Zhang M, Xu L, Hu L, Wang H, Zhao W, et al. Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival. Br J Cancer. 2013;109:1252-63 pubmed publisher
    ..This study aims to explore the expression and clinical significance of Pyk2 and its phosphorylated forms in non-small-cell lung cancer (NSCLC)...
  47. Lee S, Choi J, Han B, Kim H, Song H, Lee J, et al. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs. FEBS J. 2016;283:3613-3625 pubmed publisher
    ..The atomic coordinates and structure factors for human SYK are in the Protein Data Bank under accession codes 4XG2 (inhibitor-free form), 4XG3 (G206), 4XG4 (G207), 5GHV (O178), 4XG6 (O194), 4XG7 (O259), 4XG8 (O272), and 4XG9 (O282). ..
  48. Klaewsongkram J, Thantiworasit P, Sodsai P, Buranapraditkun S, Mongkolpathumrat P. Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4+CD25+CD134+ lymphocytes. Ann Allergy Asthma Immunol. 2016;117:514-519 pubmed publisher
    ..The reduced percentages of imatinib-induced CD4+CD25+CD134+ T cells in these patients may be associated with immune tolerance. ..
  49. Chelli D, Hamdi A, Saoudi S, Jenayah A, Zagre A, Jguerim H, et al. Clinical Assessment of Soluble FMS-Like Tyrosine Kinase-1/Placental Growth Factor Ratio for the Diagnostic and the Prognosis of Preeclampsia in the Second Trimester. Clin Lab. 2016;62:1927-1932 pubmed publisher
    ..Various reports have demonstrated that disturbances in angiogenic and antiangiogenic factors are implicated in its pathogenesis and have possible relevance in its diagnosis and prognosis...
  50. Luskin M, DeAngelo D. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Rev Hematol. 2017;:1-13 pubmed publisher
    ..Second generation, more potent and selective FLT3 inhibitors are also in development; these agents need to be compared to midostaurin...
  51. Zhang Q, Li R, Chen X, Lee S, Pan J, Xiong D, et al. Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer. Oncotarget. 2017;8:72447-72456 pubmed publisher
    ..The data provide scientific evidences for the utility of testing and comparing weekly and intermittent dosing regimens in clinical trials...
  52. Mori M, Kaneko N, Ueno Y, Yamada M, Tanaka R, Saito R, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017;: pubmed publisher
    ..No overt toxicity was seen in mouse models treated with gilteritinib. These results indicate that gilteritinib may be an important next-generation FLT3 inhibitor for use in the treatment of FLT3 mutation-positive AML. ..
  53. Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, et al. MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma. J Clin Invest. 2017;127:4179-4192 pubmed publisher
    ..Thus, our studies indicate that blocking MNK1/2 exerts potent antimelanoma effects and support blocking MNK1/2 as a potential strategy to treat patients positive for KIT mutations...
  54. Chen W, Kuang Y, Qiu H, Cao Z, Tu Y, Sheng Q, et al. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017;77:5107-5117 pubmed publisher
    ..Our findings suggest that combinatorial inhibition of IR and KIT warrants clinical evaluation as a novel therapeutic strategy in imatinib-resistant GISTs. Cancer Res; 77(18); 5107-17. ©2017 AACR. ..
  55. Rui R, Liu S, Karthikeyan A, Wang T, Niu H, Yin J, et al. Fine-mapping and identification of a novel locus Rsc15 underlying soybean resistance to Soybean mosaic virus. Theor Appl Genet. 2017;130:2395-2410 pubmed publisher
    ..was the best candidate gene attributing for the resistance of Rsc15, and that genes encoding receptor-like kinase (RLK) (i.e., Glyma.06g175100 and Glyma.06g184400) and serine/threonine kinase (STK) (i.e., Glyma.06g182900 and Glyma...
  56. Sunitha M, Srikanth L, Kumar P, Chandrasekhar C, Sarma P. Down-regulation of PAX2 promotes in vitro differentiation of podocytes from human CD34+ cells. Cell Tissue Res. 2017;: pubmed publisher
    ..These findings establish HSCs as ideal candidates for regenerative therapies of damaged podocytes. ..
  57. Zhao Y, Wu K, Wu Y, Melendez E, Smbatyan G, Massiello D, et al. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol. 2017;: pubmed publisher
    ....
  58. Kiesel B, Parise R, Wong A, Keyvanjah K, Jacobs S, Beumer J. LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma. J Pharm Biomed Anal. 2017;134:130-136 pubmed publisher
    ..9-106.5%) and precise (<6.2%CV), and met the FDA guidance for bioanalytical method validation. This LC-MS/MS assay will be an essential tool to further define the pharmacokinetics of neratinib. ..
  59. Li S, Wu Z, Ma P, Xu Y, Chen Y, Wang H, et al. Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression. Cell Death Dis. 2017;8:e3122 pubmed publisher
    ..In sum, receptor phosphorylation of EphA7, at least in part, suppress PCa tumor malignancy through targeting PI3K/Akt signaling pathways. ..
  60. Harney A, Karagiannis G, Pignatelli J, Smith B, Kadioglu E, Wise S, et al. The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors. Mol Cancer Ther. 2017;16:2486-2501 pubmed publisher
    ..Rebastinib is a promising therapy for achieving Tie2 inhibition in cancer patients. Mol Cancer Ther; 16(11); 2486-501. ©2017 AACR. ..
  61. Ianniciello A, Dumas P, Drullion C, Guitart A, Villacreces A, Peytour Y, et al. Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence. Oncotarget. 2017;8:96984-96992 pubmed publisher
    ..All together, these results suggest that autophagy is required for CML CD34+ commitment while it is dispensable for normal CD34 cells...
  62. Adjei A. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor. Clin Lung Cancer. 2007;8 Suppl 2:S74-8 pubmed
    ..There are several small-molecule inhibitors of tyrosine kinase activity of VEGF receptors in clinical trials. These are discussed in this review...